Close

Dr Kaja Abbas

Associate Professor

United Kingdom

My research area is vaccine impact modelling with a focus on estimating the health, economic, and equity impact of vaccination programmes to support evidence-based decision-making on vaccination strategies in collaboration with partners and stakeholders at the global, regional, and national levels. I have worked on impact assessment of existing and new vaccines to inform vaccine policy in varied contextual settings of low-, middle-, and high-income countries.

I hold a joint position with LSHTM and Nagasaki University. I welcome collaborations related to estimating vaccination impact in different geographic settings, and you are welcome to contact me.

Affiliations

Department of Infectious Disease Epidemiology and Dynamics
Faculty of Epidemiology and Population Health

Centres

Centre for Epidemic Preparedness and Response
Centre for Mathematical Modelling of Infectious Diseases
Vaccine Centre
Global Health Economics Centre

Teaching

Epidemiology of Infectious Diseases
Modelling and the Dynamics of Infectious Diseases

Research

Vaccine impact modelling
Vaccine epidemiology and economics

Selected Publications

Chikungunya vaccine development, challenges, and pathway toward public health impact.
Maure, C; Khazhidinov, K; KANG, H; AUZENBERGS, M; Moyersoen, P; ABBAS, K; Santos, GM L; Medina, LM H; Wartel, TA; Kim, JH; Clemens, J; Sahastrabuddhe, S;
2024
Vaccine
Research priorities to support typhoid conjugate vaccine decision-making in India: evidence assessment and stakeholder survey
MOGASALE, VV; Sinha, A; John, J; Hasan Farooqui, H; Ray, A; Chantler, T; Mogasale, V; Dhoubhadel, BG; EDMUNDS, WJ; Clark, A; ABBAS, K;
2024
BMJ public health
Typhoid conjugate vaccine implementation in India: A review of supportive evidence.
Mogasale, VV; Sinha, A; John, J; Hasan Farooqui, H; Ray, A; CHANTLER, T; Mogasale, V; Gopal Dhoubhadel, B; John Edmunds, W; CLARK, A; ABBAS, K;
2024
Vaccine: X
Programmatic considerations and evidence gaps for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: Stakeholder analysis.
AUZENBERGS, M; Maure, C; KANG, H; CLARK, A; BRADY, O; Sahastrabuddhe, S; ABBAS, K;
2024
PLoS neglected tropical diseases
Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: a modelling study.
Hartner, A-M; Li, X; Echeverria-Londono, S; Roth, J; ABBAS, K; AUZENBERGS, M; De Villiers, MJ; Ferrari, MJ; Fraser, K; FU, H; Hallett, T; Hinsley, W; JIT, M; Karachaliou, A; Moore, SM; Nayagam, S; Papadopoulos, T; Perkins, TA; Portnoy, A; Minh, QT; VYNNYCKY, E; Winter, AK; Burrows, H; Chen, C; Clapham, HE; ... Gaythorpe, KA M.
2024
The Lancet Global health
Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study.
KANG, H; AUZENBERGS, M; Clapham, H; Maure, C; Kim, J-H; Salje, H; Taylor, CG; LIM, A; CLARK, A; EDMUNDS, WJ; Sahastrabuddhe, S; BRADY, OJ; ABBAS, K;
2024
The Lancet Infectious Diseases
State transitions across the Strep A disease spectrum: scoping review and evidence gaps.
Parajulee, P; Lee, J-S; ABBAS, K; Cannon, J; Excler, JL; Kim, JH; Mogasale, V;
2024
BMC Infectious Diseases
Vaccine value profile for Chikungunya.
Flandes, X; Hansen, CA; Palani, S; ABBAS, K; Bennett, C; Caro, WP; Hutubessy, R; Khazhidinov, K; Lambach, P; Maure, C; Marshall, C; Rojas, DP; Rosewell, A; Sahastrabuddhe, S; Tufet, M; Wilder-Smith, A; Beasley, DW C; Bourne, N; Barrett, AD T;
2023
Vaccine
See more information